Inspira Technologies has announced promising results from its collaboration with Ennocure MedTech Ltd., revealing that their novel bio-electronic patch achieved over 95% reduction in bacterial presence during ex-vivo testing. The technology, designed to prevent bloodstream infections in critically ill patients, demonstrated significant efficacy within just four hours of application.
The ex-vivo porcine skin model testing showed the bio-electronic patch maintained its effectiveness over a 24-hour period. Unlike traditional antimicrobial dressings that rely on chemical agents, this innovative approach uses physical electric stimulation to prevent pathogen growth on treated surfaces.
"We believe that these initial results represent an important milestone in our development of next-generation infection prevention technology," said Dagi Ben-Noon, CEO of Inspira. "With an estimated 250,000 bloodstream infections related to intravenous lines occurring worldwide each year, we believe this novel approach could potentially offer significant advantages in critical care settings."
Technology Design and Advantages
The bio-electronic technology addresses several key challenges associated with traditional IV dressings. Key features include:
- Prevention of bacterial growth through physical rather than chemical means
- Potential for extended wear time, reducing frequency of dressing changes
- Applicability to both skin surface and cannula areas
- Real-time monitoring capabilities
Testing was conducted following adjusted standardized protocols, including the AATCC TM100 standard for antimicrobial performance. Results consistently showed greater bacterial reduction under active patches compared to controls.
Clinical Significance
Bloodstream infections represent a significant challenge in critical care settings. Intravenous catheters, while essential for medication delivery and monitoring, create potential entry points for pathogens. Current prevention methods include antimicrobial dressings and strict adherence to insertion and maintenance protocols, but infection rates remain concerning.
The development of a bio-electronic approach could potentially transform infection prevention strategies by providing a non-chemical alternative that addresses multiple aspects of infection control simultaneously.
About the Companies
Ennocure MedTech Ltd. specializes in developing bio-electronic wound dressings. Their proprietary technology is designed to prevent bacterial infections while providing remote wound monitoring and infection alerts based on AI-driven personalized therapy.
Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) is an innovative medical technology company focused on life support and respiratory treatment. The company has developed Augmented Respiration Technology (INSPIRA ART), designed to revolutionize the $19 billion mechanical ventilation market. Their FDA-cleared INSPIRA ART100 system has received regulatory approvals for Cardiopulmonary Bypass procedures in both the U.S. and Israel, with additional approvals in Israel for Extra Corporeal Membrane Oxygenation.
The company's product pipeline includes the INSPIRA ART (Gen 2), INSPIRA Cardi-ART, and HYLA blood sensor technology, which aims to provide continuous, real-time blood monitoring without blood draws, targeting the $2.5 billion blood gas analyzer market. These pipeline products are still in development and have not yet received regulatory approval.
Future Outlook
While these initial results are promising, further testing will be necessary to validate the technology's effectiveness in clinical settings. The development represents a potential breakthrough in infection prevention for critical care patients, particularly those requiring long-term intravenous access.
If successful in further development stages, this bio-electronic approach could significantly reduce healthcare-associated infections, potentially decreasing hospital stays, reducing antibiotic use, and improving patient outcomes in intensive care settings.
